Skip to main content

Advertisement

Table 1 Study population according to hospital mortality (N (%)—median [IQR 25–75])

From: Increased mortality in hematological malignancy patients with acute respiratory failure from undetermined etiology: a Groupe de Recherche en Réanimation Respiratoire en Onco-Hématologie (Grrr-OH) study

(N (%)—median [IQR 25–75]) Alive at hospital discharge (n = 349) Patients who died (n = 255, 42%) p value
Age (year) 60 [50–69] 61 [51–71] 0.43
Malignancy    
 Acute myeloid leukemia 90 (25.8%) 78 (30.6%) 0.37
 Non-Hodgkin lymphoma 96 (27.5%) 68 (26.7%)  
 Myeloma 49 (14%) 32 (12.5%)  
 Chronic lymphocytic leukemia 32 (9.2%) 23 (9%)  
 Acute lymphoblastic leukemia 19 (5.4%) 19 (7.4%)  
 Myelodysplastic syndrome 18 (5.2%) 12 (4.7%)  
 Hodgkin’s disease 14 (4%) 4 (1.6%)  
 Others 31 (8.9%) 19 (7.5%)  
Disease status at admission    
 Earliest phase 120 (34.4%) 88 (34.5%) 0.86
 Progression 137 (39.3%) 103 (40.4%)  
 Complete or partial remission 83 (23.8%) 55 (21.6%)  
 Unknown 9 (2.5%) 9 (3.5%)  
Stem cell transplantation    
 Autologous 39 (11.2%) 23 (9.1%) 0.03
 Allogeneic 50 (14.3%) 57 (22.4%)  
Poor performance status 55 (15.8%) 69 (27.1%) 0.001
Time from hospital to ICU admission >24 h 159 (46%) 96 (38%) 0.061
Neutropenia 85 (24.4%) 97 (38%) 0.0004
Respiratory rate at admission (/min) 32 [25–37] 35 [25–39] 0.002
Invasive mechanical ventilation at day 1 107 (30.7%) 143 (56.1%) <0.0001
SOFA score >7 108 (32.2%) 162 (66.7%) <0.0001
ARF etiologies    
 Infectious etiologies 162 (46.4%) 106 (41.6%) <0.0001
  Clinically documented 60 (17.2%) 21 (8.2%)  
  Bacterial infection 56 (16%) 54 (21.2%)  
  Viral infection 16 (4.6%) 8 (3.2%)  
  Other 30 (8.6%) 23 (9%)  
 Non-infectious lung involvement 127 (36.4%) 69 (27.1%)  
  Malignant infiltrate 25 (7.2%) 18 (7.1%)  
  Drug-related lung toxicity 4 (1.1%) 0 (0%)  
  Cardiac pulmonary edema 48 (13.8%) 17 (6.7%)  
  Other 50 (14.3%) 34 (13.3%)  
 Opportunistic infections 28 (8%) 34 (13.3%)  
  Invasive pulmonary aspergillosis 6 (1.7%) 24 (9.4%)  
  Pneumocystis jirovecii infections 18 (5.1%) 4 (1.6%)  
  Other invasive fungal infections 3 (0.9%) 2 (0.7%)  
  Other 1 (0.3%) 4 (1.6%)  
 Undetermined 32 (9.2%) 46 (18%)  
  1. Results were expressed as median and 25th and 75th quartiles [Q1–Q3] for quantitative data and numbers and percentages for categorical data. Marginal association between single variables and outcome was assessed by Wilcoxon rank-sum tests for quantitative variables and Fisher’s exact test or Chi-square test with Yates continuity correction for categorical variables when Fisher’s exact test was computationally impossible
  2. CR complete remission, NA not available, PR partial remission, IQR inter-quartile range